CClinicalTrials.gg
Status unknownNCT04923451CASUpdated Jun 11, 2021

tDCS in Treatment of Craving in Sexual Addiction

An interventional study of Active Trans-cranial direct current stimulation (tDCS) and Sham Trans-cranial direct current stimulation (tDCS) in Sexual Addiction and Hypersexualism, sponsored by Centre Hospitalier St Anne. Status unknown. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

In patients with addiction to a substance, an increase in activity in the prefrontal cortex induced by transcranial Direct Current Stimulation -tDCS (non-invasive technique, modulating cortical activity by applying low-intensity electrical currents between two electrodes),may help reduce craving in people addicted to alcohol and tobacco. By analogy with addictive behavior with a substance, the craving observed in certain behavioral addictions would involve the same neural circuits.

The main hypothesis is to reduce the sexual craving associated with the viewing of erotic images during active brain stimulation compared to placebo stimulation. Functional MRI will allow to better understand the neural circuits involved in sexual addiction and in the expected inhibition of sexual arousal by tDCS in sexual addictions during visualization erotic images.

Read the detailed description

The concept of sexual addiction appeared in American literature about 20 years ago. The term sexual addiction describes an excessive, increasing, and especially uncontrolled frequency of sexual behavior, as a conventional rule, associated with a compelling and irrepressible sexual desire (craving), which persists in spite of the possible negative consequences and personal suffering of the subject. The prevalence of this condition is estimated to be approximately 3-6% in the general population in the United States, it is independent of the socio-cultural environment. The pathophysiology of sexual addictions remains very poorly understood.

Numerous studies have focused on substance addictions and their pathophysiology. The mesolimbic dopaminergic system plays a major role in addictive behavior. The prefrontal cortex and the basolateral region of the amygdala play an important role in the craving and may cause relapse in subjects. In subjects with sexual addiction, only one controlled study has been conducted on the role of antidepressant treatment in the reduction of craving. The objective of the study is not only to evaluate the efficacy of tDCS neurostimulation in this disorder but also to identify the brain structures involved in this addictive disorder.

02

Conditions studied

  • Sexual Addiction
  • Hypersexualism

Browse trials for

Keywords

  • Sexual Addiction
  • Hypersexualism
  • Neurostimulation
  • tDCS
  • fMRI
03

In context

Behavior, Addictive

540 studies on the registry are indexed under Behavior, Addictive; 134 are open to participants now.

This study's planned enrollment of 50 is below the median of 72 across 391 interventional studies indexed under Behavior, Addictive.

Browse Behavior, Addictive studies →

Lead sponsor

Centre Hospitalier St Anne is the lead sponsor of 99 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-60 year old male
  • Heterosexual
  • Right-handed (Manual laterality test)
  • With a sexual addiction (PEACCE Tool> 3 and Carnes ≥ 13/25) except for controls
  • Having signed a written and informed consent
  • Subject benefiting from social security

Exclusion criteria

Exclusion Criteria:

  • Subject presenting a medical pathology requiring drug treatment,
  • Severe psychiatric pathology (bipolar disorder, hyperactivity or schizophrenia) or another addiction (alcohol, illicit substances or behavioral addiction)
  • Subject consuming psychotropic drugs in progress or during the last month
  • Subject not understanding French
  • Subject under tutorship or curatorship
  • Subjects with neurological disease including epilepsy or a history of head trauma
  • Subjects hospitalized in enforced hospitalization
  • Subject presenting a contraindication to tDCS: subject with an electrical or metal brain implant
  • Subject with a contraindication to MRI
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Patient with sexual addiction - active stimulation

    25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days

    Device: Active Trans-cranial direct current stimulation (tDCS)

  • Sham comparator
    Patient with sexual addiction - sham stimulation (placebo)

    25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days

    Device: Sham Trans-cranial direct current stimulation (tDCS)

Interventions

  • DeviceActive Trans-cranial direct current stimulation (tDCS)

    5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed

  • DeviceSham Trans-cranial direct current stimulation (tDCS)

    5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed

06

What researchers measure

Primary outcomes

  1. Efficacy of tDCS in treatment of craving of sexual addiction

    The primary outcome is to assess the effectiveness of tDCS treatment on the reduction of the craving by comparing before and after active tDCS stimulation in response to erotic-pornographic images. Efficacy will be quantified by a sexual craving scale associated with erotico-pornographic images before and after tDCS stimulation. A significant decrease in craving and score on the scale is expected after tDCS stimulation. compared to control subjects. Images of social and neutral interactions will be used as comparison of expected changes. The scale used is the PATHOS scale: brief sexual addiction screening questionnaire.

    Time frame: 3 years

  2. Efficacy of tDCS in treatment of sexual addiction in subjective emotional response

    For the evaluation of efficacy of tDCS in emotional response, indirect measurement of craving, visual emotional responses scales (Likert) will be used during visualization of erotico-pornographic images, before and after stimulation. The "desire" will be quantified on a Likert scale from 0 to 7.

    Time frame: 3 years

  3. Efficacy of tDCS in treatment of sexual addiction in objective emotional response

    An assessment of emotional responses will also be done using heart rate measure during visualization of images in fMRI, before and after stimulation by tDCS

    Time frame: 3 years

Secondary outcomes

  1. Brain structures involved in sexual addiction

    The secondary objectives are the evaluation of the brain structures involved in sexual addiction, especially craving, and the study of the modifications of the circuits involved after the application of tDCS. A modification of the BOLD signal in fMRI in the mesolimbic reward system as well as in the dorsolateral prefrontal cortex, orbitofrontal cortex and the amygdala in response to erotic images is expected after tDCS. 50 patients with sexual addiction will be compared with 25 healthy subjects for this objective

    Time frame: 3 years

  2. Evaluation of Impulsivity with The Barratt Impulsiveness Scale

    In addition, the evaluation of impulsivity and inhibition capacities of the frontal cortex will be conducted.Changes in impulsivity scale scores and motor inhibition task scores are expected after tDCS.

    Time frame: 3 years

  3. Evaluation of Impulsivity with UPPS-P Impulsive Behavior Scale

    A decrease in scores on this scale is expected after stimulation compared to patients who received placebo stimulation.

    Time frame: 3 years

  4. Evaluation Evaluation of Impulsivity with Stop Signal Task

    A decrease in scores on this scale is expected after stimulation, compared to patients who received placebo stimulation.

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Garcia FD, Thibaut F. Sexual addictions. Am J Drug Alcohol Abuse. 2010 Sep;36(5):254-60. doi: 10.3109/00952990.2010.503823. PubMed 20666699 ↗
  • Malandain L, Blanc JV, Ferreri F, Thibaut F. Pharmacotherapy of Sexual Addiction. Curr Psychiatry Rep. 2020 May 7;22(6):30. doi: 10.1007/s11920-020-01153-4. PubMed 32377953 ↗
  • Wainberg ML, Muench F, Morgenstern J, Hollander E, Irwin TW, Parsons JT, Allen A, O'Leary A. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry. 2006 Dec;67(12):1968-73. doi: 10.4088/jcp.v67n1218. PubMed 17194276 ↗
  • Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15037-42. doi: 10.1073/pnas.1010654108. Epub 2011 Mar 14. PubMed 21402948 ↗
  • Voon V, Mole TB, Banca P, Porter L, Morris L, Mitchell S, Lapa TR, Karr J, Harrison NA, Potenza MN, Irvine M. Neural correlates of sexual cue reactivity in individuals with and without compulsive sexual behaviours. PLoS One. 2014 Jul 11;9(7):e102419. doi: 10.1371/journal.pone.0102419. eCollection 2014. PubMed 25013940 ↗
  • Rosenberg KP, Carnes P, O'Connor S. Evaluation and treatment of sex addiction. J Sex Marital Ther. 2014;40(2):77-91. doi: 10.1080/0092623X.2012.701268. Epub 2013 Jun 21. PubMed 23790248 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04923451
Lead sponsor
Centre Hospitalier St Anne
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jul 1, 2021 (estimated)
Primary completion
Nov 1, 2023 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Jun 11, 2021

Study contacts

Leo Malandain, MD
Contact
leo.malandain@aphp.fr
0033158411678
Florence Thibaut, MD-PHD
Contact
florence.thibaut@aphp.fr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion